A Study of Portal Vein Blood Testing to Predict Treatment Response Compared with CT Scan in Patients with Advanced Pancreatic Cancer

EUS-guided Portal Vein Sampling for Circulating Tumor Cells to Predict Treatment Response Compared with CT Imaging in Unresectable Pancreatic Ductal Adenocarcinoma: A Prospective Observational Study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20260726005

Enrollment

Registered

2026-07-26

Start date

2026-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable pancreatic ductal adenocarcinoma Pancreatic Ductal Adenocarcinoma Portal Vein Circulating Tumor Cells Endosonography Tomography X Ray Computed Treatment Outcome Biomarkers Tumor Pancreatic Neoplasms

Interventions

Participants will undergo EUS guided portal vein blood sampling during endoscopic ultrasound using a fine needle aspiration needle to obtain portal venous blood for circulating tumor cell analysis. Pe

Experimental Other

EUS guided portal vein blood sampling

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed non metastatic pancreatic ductal adenocarcinoma classified as AJCC stage I to III 2. Disease assessed as unresectable by a multidisciplinary team 3. Planned to receive chemotherapy radiotherapy or combined treatment according to standard care 4. Eastern Cooperative Oncology Group performance status 0 to 2 5. Estimated life expectancy of at least 6 months 6. Able and willing to provide written informed consent

Exclusion criteria

Exclusion criteria: 1. Uncorrectable coagulopathy defined as INR greater than 1.5 activated partial thromboplastin time greater than two times the upper limit of normal or platelet count less than 50000 after appropriate correction 2. Uncontrolled infection or sepsis 3. Poor visualization of the portal vein during endoscopic ultrasound 4. Contraindication to upper gastrointestinal endoscopy or sedation 5. Unable or unwilling to comply with study procedures or follow up

Design outcomes

Primary

Measure	Time frame
Portal vein circulating tumor cell count Baseline during EUS procedure Circulating tumor cell enumeration using laboratory analysis of portal vein blood,Portal vein circulating tumor cell count One month after baseline Circulating tumor cell enumeration using laboratory analysis of portal vein blood,Progression free survival 12 months after baseline Clinical follow up and computed tomography	—

Secondary

Measure	Time frame
Peripheral blood circulating tumor cell count Baseline during EUS procedure Circulating tumor cell enumeration using laboratory analysis of portal vein blood,Peripheral blood circulating tumor cell count One month after baseline Circulating tumor cell enumeration using laboratory analysis of portal vein blood	—

Countries

Thailand

Contacts

Public ContactPradermchai Kongkam

chulalongkorn university

kongkam@hotmail.com022564356

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026